GENE ONLINE|News &
Opinion
Blog

2022-06-23| Trials & Approvals

FDA Blesses Merck’s Pneumococcal Vaccine for Pediatric Use

by Fujie Tham
Share To

Merck, or MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved an expanded indication for its 15-valent pneumococcal conjugate vaccine – Vaxneuvance to include children from 6 weeks to 17 years old.

Vaxneuvance offers better protection against more pneumonia-causing variants than the standard of care Pfizer 13-valent pneumococcal conjugate vaccine (PCV13), this approval gave Merck an even better edge against the Pfizer competitor.

According to the CDC, about 2,000 cases of serious disease (bacteremia, pneumonia with bacteremia, and meningitis) occur each year in children under five in the United States, and around 1 out of 12 children who get pneumococcal meningitis dies.

Related article: Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults

 

First Pediatric Pneumococcal Conjugate Vaccine Approved in Almost a Decade

 

The FDA approval was based on data from seven randomized double-blind clinical studies in infants, children, and adolescents, the trials also proved that Vaxneuvance can be administered as per scheduled or in a “catch-up” setting for older children. Additionally, the trials support its use in special populations, such as preterm infants and children living with HIV or sickle cell disease.

First approved by the FDA in July 2021 for adults, Merck’s vaccine provides additional protection against Streptococcus pneumoniae serotypes F22 and F33, which are two of the top five serotypes causing childhood cases of invasive pneumococcal disease (IPD). IPD means that bacteria invade parts of the body that are normally free from germs. Examples of IPD are bacteremia (an infection in the blood) and meningitis (an infection of the coverings of the brain and spinal cord).

Vaxneuvance’s expanded pediatric indications mean that Merck can tap into the demands accounting for almost 80% of the market for pneumococcal vaccines, while Pfizer is catching up with both protections and pediatric indications.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Finds Carcinogen In Merck’s Diabetes Drug, Allows Continued Sales To Avoid Shortage
2022-08-11
Merck Dangles $1.1 Billion For Cerevance To Discover New Targets For Alzheimer’s
2022-08-10
M&A
Pfizer Acquires Global Blood Therapeutics and its sickle cell disease expertise for $5.4 billion
2022-08-09
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!